017180 — Myungmoon Pharm Co Balance Sheet
0.000.00%
- KR₩53bn
- KR₩152bn
- KR₩195bn
Annual balance sheet for Myungmoon Pharm Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
R2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | Interim Report | ARS | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 7,097 | 5,264 | 8,064 | 4,558 | 5,945 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 30,345 | 34,700 | 38,928 | 42,190 | 46,550 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 67,466 | 70,707 | 81,436 | 80,329 | 92,072 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 142,861 | 141,777 | 140,196 | 161,994 | 165,856 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 223,263 | 230,450 | 236,549 | 257,988 | 272,455 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 113,088 | 110,821 | 116,373 | 92,660 | 96,363 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Funded Status | |||||
| Total Liabilities | 143,006 | 140,928 | 153,096 | 161,137 | 173,715 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Unrealized Gain / Loss | |||||
| Other Equity | |||||
| Total Equity | 80,257 | 89,522 | 83,453 | 96,851 | 98,741 |
| Total Liabilities & Shareholders' Equity | 223,263 | 230,450 | 236,549 | 257,988 | 272,455 |
| Total Common Shares Outstanding |